Regeneron Pharms (NASDAQ: REGN) was downgraded by equities research analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating in a research note issued to investors on Friday.
A number of other firms have also recently commented on REGN. Analysts at Robert W. Baird reiterated an “outperform” rating on shares of Regeneron Pharms in a research note to investors on Wednesday, April 25th. Separately, analysts at Bank of America (NYSE: BAC) raised their price target on shares of Regeneron Pharms from $135.00 to $146.00 in a research note to investors on Monday, April 23rd. Finally, analysts at Goldman Sachs (NYSE: GS) initiated coverage on shares of Regeneron Pharms in a research note to investors on Monday, April 2nd. They set a “buy” rating and a $144.00 price target on the stock.
Regeneron Pharms traded down 1.92% on Friday, hitting $137.32. Regeneron Pharms has a 1-year low of $42.83 and a 1-year high of $145.04. The company’s market cap is $12.640 billion.
The company last announced its quarterly results on Thursday, April 26th. It reported $0.37 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.33) EPS by $0.70. The company’s quarterly revenue was up 106.6% on a year-over-year basis. Analysts expect that Regeneron Pharms will post $0.10 EPS next quarter.
Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company. Regeneron discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions.